Biological interactions between herpesviruses and cyclooxygenase enzymes

Reviews in Medical Virology

Volumn 16, Issue 6, 2006, Pages 393-403

  Reynolds, Ashley E ^a   Enquist, L W ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BMS 279652; BMS 279654; BMS 279655; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FR 122407; IBUPROFEN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

DRUG MECHANISM; ENZYME INHIBITION; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; LYMPHOID CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; VIRION; VIRUS CELL INTERACTION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; HERPESVIRIDAE; HERPESVIRIDAE INFECTIONS; HUMANS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS;

EID: 33751088529     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.519     Document Type: Review

References (76)

1. Steer SA, Corbett JA. The role and regulation of COX-2 during viral infection. Viral Immunol 2003; 16: 447-460.
2. Ongrádi J, Telekes A. Relationship between the prostaglandin cascade and virus infection. Acta Virol 1990; 34: 380-400.
3. Garavito RM, DeWitt DL. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1999; 1441: 278-287.
4. Garavito RM, Malkowski MG, DeWitt DL. The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 2002; 68-69: 129-152.
5. Garavito RM, Mulichak AM. The structure of mammalian cyclooxygenases. Annu Rev Biophys Biomol Struct 2003; 32: 183-206.
6. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-182.
7. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33157-33160.
8. Hla T, Bishop-Bailey D, Liu CH, et al. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol 1999; 31: 551-557.
9. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004; 56: 387-437.
10. Vane JR, Bakhle YS, Botting, RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
11. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-7388.
12. Chandrasekharan NV, Dai H, Roos KLT, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-13931.
13. Davies NM, Good RL, Roupe KA, et al. Cyclooxygenase-3: axiom, dogma, anomaly, enigma or splice error? - not as easy as 1, 2, 3. J Pharm Pharm Sci 2004; 7: 217-226.
14. Kis B, Snipes JA, Busija DW. Acetominophen and the cyclooxygenase 3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005; 315: 1-7.
15. Qin N, Zhang SP, Reitz TL et al. Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention. J Pharmacol Exp Ther 2005; 315: 1298-1305.
16. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-235.
17. Bakhle YS. Structure of COX-1 and COX-2 enzymes and their interaction with inhibitors. Drugs Today (Barc.) 1999; 35: 237-250.
18. Loll PJ, Picot D, Garavito RM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995; 2: 637-643.
19. Smith WL, DeWitt DL. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin Nephrol 1995; 15: 179-194.
20. Spencer AG, Woods JW, Arakawa T, et al. Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy. J Biol Chem 1998; 273: 9886-9893.
21. Spencer AG, Thuresson E, Otto JC, et al. The membrane binding domains of prostaglandin endoperoxide H synthases 1 and 2. Peptide mapping and mutational analysis. J Biol Chem 1999; 274: 32936-32942.
22. Berg DJ, Zhang J, Lauricella DM, et al. IL-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J Immunol 2001; 166: 2674-2680.
23. Steer SA, Moran JM, Maggi LB, et al. Regulation of cyclooxygenase-2 expression by macrophages in response to double-stranded RNA and viral infection. J Immunol 2003; 170: 1070-1076.
24. Xie WL, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-2696.
25. O'Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA 1992; 89: 4888-4892.
26. Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992: 267: 7991-7994.
27. Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992; 267: 25934-25938.
28. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804.
29. Ristimaki A, Garfinkel S, Wessendorf, J, et al. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 1994; 69: 11769-11775.
30. Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J Gen Virol 1969; 4: 203-214.
31. Newton, AA. Inhibitors of prostaglandin synthesis as inhibitors of herpes simplex virus replication. Adv Ophthal 1979; 38: 58-63.
32. Harbour DA, Blyth WA, Hill TJ. Prostaglandins enhance spread of herpes simplex virus in cell cultures. J Gen Virol 1978; 41: 87-95.
33. Harbour DA, Hill TJ, Blyth WA. Prostaglandins enhance intercellular adhesion of Vero cells infected with herpes simplex virus. J Gen Virol 1983; 64: 507-512.
34. Khyatti M, Menezes J. The effect of indomethacin, prostaglandin E2 and interferon on the multiplication of herpes simplex virus type 1 in human lymphoid cells. Antiviral Res 1990; 14: 161-172.
35. Inglot AD, Woytoń A. Topical treatment of cutaneous herpes simplex in humans with the non-steroid anti-inflammatory drugs: mefenamic acid and indomethacin in dimethylsulfoxide. Arch Immunol Ther Exp (Warz) 1971; 19: 555-566.
36. Chang TW. Prostaglandin synthetase inhibitors in primary herpes infection. J Infect 1980; 2: 374-375.
37. Wachsman M, Aurelian L, Burnett, JW. The prophylactic use of cyclooxygenase inhibitors in recurrent herpes simplex infections. Br J Dermatol 1990; 123: 375-380.
38. Hill JM, Lukiw WJ, Gebhardt BM, et al. Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Virus Genes 2001; 23: 273-280.
39. Ray N, Enquist LW. Transcriptional response of a common permissive cell type to infection by two diverse alphaherpesviruses. J Virol 2004; 78: 3489-3501.
40. Ray N. Host transcriptional response to alphaherpesvirus infections: implications of COX-2 induction on virus growth. Princeton University Ph.D. Thesis 2004; Princeton, NJ, USA.
41. Ray N, Bisher ME, Enquist LW. Cyclooxygenase-1 and -2 are required for production of infectious pseudorabies virus. J Virol 2004; 78: 12964-12974.
42. Pomeranz LE, Reynolds AE, Hengartner CJ. Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine. Microbiol Mol Biol Rev 2005; 69: 462-500.
43. Mettenleiter TC, Minson T, Wild P. Egress of alphaherpesviruses. J Virol 2006; 80: 1610-1612.
44. Bishop-Bailey D, Hla T, Mitchell JA. Cyclooxygenase-2 in vascular smooth muscle. Int J Mol Med 1999; 3: 41-48.
45. Speir E, Yu ZX, Ferrans VJ, et al. Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary artery smooth muscle cells. Circ Res 1998; 83: 210-216.
46. Zhu H, Cong JP, Mamtora G, et al. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 14470-14475.
47. Zhu H, Cong JP, Yu D, et al. Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc Natl Acad Sci USA 2002; 99: 3932-3937.
48. Hooks JJ, Chin MS, Srinivasan K, et al. Human cytomegalovirus induced cyclooxygenase-2 in human retinal pigment epithelial cells augments viral replication through a prostaglandin pathway. Microbes Infect 2006; 8: 2236-2244. doi:10.1016/j.micinf.2006.04.010.
49. Janelle ME, Gravel A, Gosselin J, et al. Activation of monocyte cyclooxygenase-2 gene expression by human herpesvirus 6. J Biol Chem 2002; 277: 30665-30674.
50. Rue CA, Jarvis MA, Knoche AJ, et al. A cyclooxygenase-2 homologue encoded by rhesus cytomegalovirus is a determinant for endothelial cell tropism. J Virol 2004; 78: 12529-12536.
51. Shelby BD, Nelson A, Morris C. Gamma-herpesvirus neoplasia: a growing role for COX-2. Microsc Res Tech 2005; 68: 120-129.
52. Symensma TL, Martinez-Guzman D, Jia Q, et al. COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. J Virol 2003; 77: 12753-12763.
53. Naranatt PP, Krishnan HH, Svojanovsky SR, et al. Host gene induction and transcriptional reprogramming in Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)-infected endothelial, fibroblast, and B cells: insights into modulation events early during infection. Cancer Res 2004; 64: 72-84.
54. Sharma-Walia N, Raghu H, Sadagopan S, et al. Cyclooxygenase 2 induced by Kaposi's Sarcoma-associated herpesvirus early during in vitro infection of target cells plays a role in the maintenance of latent viral gene expression. J Virol 2006; 80: 6534-6552.
55. Tan KB, Putti TC. Cyclooxygenase 2 expression in nasopharyngeal carcinoma: immunohistochemical findings and potential implications. J Clin Pathol 2005; 58: 535-538.
56. Murono S, Inoue H, Tanabe T, et al. Induction of cycooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA 2001; 98: 6905-6910.
57. Murono S, Yoshizaki T, Sato H, et al. Aspirin inhibits tumour invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 2000; 60: 2555-2561.
58. Kaul R, Verma SC, Murakami M, et al. Epstein-Barr protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1. J Virol 2006; 80: 1321-1331.
59. 2 biosynthesis in human monocytes. J Immunol 2000; 164: 6467-6473.
60. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073.
61. Chen N, Reiss CS. Distinct roles of eicosanoids in the immune response to viral encephalitis: or why you should take NSAIDS. Viral Immunol 2002: 15: 133-146.
62. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-910.
63. Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy 2005; 4: 335-340.
64. Bratcher DF, Harrison CJ, Bourne N, et al. Effect of indomethacin on ultraviolet radiation-induced recurrent herpes simplex virus disease in guinea-pigs. J Gen Virol 1993; 74: 1951-1954.
65. Kurane I, Tsuchiya Y, Sekizawa T, et al. Inhibition by indomethacin of in vitro reactivation of latent herpes simplex virus type 1 in murine trigeminal ganglia. J Gen Virol 1984; 65: 1665-1674.
66. Biswas PS, Banerjee K, Kim B, et al. Role of inflammatory cytokine-induced cycloxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis. J Virol 2005; 79: 10589-10600.
67. Gebhardt BM, Varnell ED, Kaufman, HE. Inhibition of cyclooxygenase 2 synthesis suppresses herpes simplex virus type 1 reactivation. J Ocul Pharmacol Ther 2005; 21: 114-120.
68. Yates F, Centifanto YM, Caldwell DR. The effect of modulating the synthesis of arachidonic acid cascade products on HSV lesion recurrence. Curr Eye Res 1987; 6: 99-104.
69. 3 prostaglandin receptor in acute herpetic but not postherpetic pain in mice. Neuropharmacology 2005; 49: 283-292.
70. Bruggeman CA. Does cytomegalovirus play a role in atherosclerosis? Herpes 2000; 7: 51-54.
71. Fries S, Grosser T. The cardiovascular pharmacology of COX-2 inhibition. Hematology (Am Sci Hematol Educ Program) 2005; 445-451.
72. Ismail A, Khosravi H, Olson H. The role of infection in atherosclerosis and coronary artery disease; a new therapeutic target. Heart Dis 1999; 1: 233-240.
73. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291.
74. Martelius TJ, Wolff H, Bruggeman CA, et al. Induction of cyclo-oxygenase-2 by acute liver allograft rejection and cytomegalovirus infection in the rat. Transpl Int 2002; 15: 610-614.
75. Gao LH, Zheng SS. Cytomegalovirus and chronic allograft rejection in liver transplantation. World J Gastroenterol 2004; 10: 1857-1861.
76. Heitman CRK, Waite M, Kucera LS. Studies of phospholipase and cyclooxygenase activities in herpes simplex virus type 2-transformed rat cells. Carcinogenesis 1989; 10: 2059-2065.